HMG Purification via Multimodal Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current purification methods for human menopausal gonadotropin (HMG) fail to completely remove non-gonadotropin proteins like plasma serine protease inhibitor, afamin, insulin-like growth factor binding protein 7, zinc alpha-2-glycoprotein, and albumin, which co-purify with active principles, affecting the bioactivity ratio and purity of HMG-HP.
Innovation Solution
Incorporating a multimodal chromatography step using a strong anion exchanger like Capto-adhere™ to specifically purify the LH bioactive fraction (Fraction J3) by modifying conductivity while maintaining constant pH, thereby removing contaminants and achieving higher purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional purification methods are used for HMG, then the manufacturing process is simple, but the purity of the final product is insufficient due to co-purification of non-gonadotropin proteins
Solution Approach 1:
The purification process is divided into multiple sequential chromatographic steps, each targeting specific contaminants. The method segments the purification task into: (1) initial purification to remove bulk contaminants, (2) multimodal chromatography step to specifically remove co-purifying proteins like afamin and protease inhibitors, and (3) final polishing steps to achieve ultra-purity. This segmentation allows each step to focus on specific impurities rather than attempting to remove all contaminants in a single complex operation.
Solution Approach 2:
The patent introduces intermediate purification steps with specific chromatography media that act as mediators between the crude extract and the final purified product. These intermediate steps use specially designed chromatography resins with particular selectivity for contaminant proteins, serving as bridging stages that progressively enhance purity without requiring the final step to handle all purification challenges alone.
2Manufacturing precision
If additional purification steps are added to remove contaminants, then the purity of HMG increases, but the process complexity and time increase
Solution Approach 1:
The patent employs parameter changes in the chromatography conditions to optimize the balance between purification effectiveness and processing time. This includes adjusting flow rates, buffer compositions, pH values, and salt concentrations to achieve rapid separation of contaminants from gonadotropins. The multimodal chromatography step uses optimized gradients that quickly elute contaminants while retaining and then releasing the target hormones, reducing the time each purification step requires.
Solution Approach 2:
The purification protocol includes preliminary steps that remove the bulk of contaminants before the critical multimodal chromatography step. By performing preliminary removal of abundant impurities in earlier, faster steps, the subsequent high-resolution purification steps operate on a cleaner sample, reducing their required duration and increasing overall process efficiency.
3Manufacturing precision
If conventional chromatography is used, then the process is straightforward, but non-gonadotropin proteins like afamin and protease inhibitors co-purify with active principles
Solution Approach 1:
The patent utilizes composite chromatography media with multiple functional properties in the multimodal chromatography step. These composite resins combine different binding mechanisms (ionic interaction, hydrophobic interaction, hydrogen bonding) within a single material, enabling simultaneous removal of various types of contaminant proteins that have different physicochemical properties. This composite approach achieves high purity in a single step rather than requiring multiple separate conventional chromatography steps.
Solution Approach 2:
The multimodal chromatography resin performs multiple purification functions simultaneously - removing acidic proteins, basic proteins, and other contaminant classes in a single pass through the column. This multi-functional resin replaces what would otherwise require several specialized chromatography steps, simplifying the overall manufacturing process while achieving superior purity results.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in HMG-UP with significantly increased FSH and LH bio-potency, achieving a 175% higher purity compared to HMG-HP, with the contaminants being undetectable, and maintaining the essential bioactivity ratio of 1:1.
Implementation Method 1
purification of the gonadotropin of Fraction J3 using a strong anion exchanger with multimodal functionality, eluting with a buffer at a constant pH but modifying the conductivity
Implementation Method 2
multimodal chromatography step using a strong anion exchanger like Capto-adhere™
Implementation Method 3
specifically a multimodal strong anion exchanger, Capto-adhere™ (Fraction J3-UP)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention refers to a method of purification of HMG(human menopausal gonadotropin) by multimodal chromatography in order to obtain HMG-UP (human menopausal gonadotropin with ultra-purity grade) composition.